Obesity Treatments, M&A Activity To Take Center Stage During Upcoming JPM Healthcare Conference

Benzinga03:12

Goldman Sachs lowered Amgen's Target Price to $370.

Gelonghui, January 9 | Goldman Sachs: Downgraded Amgen's Target Price from $375 to $370, maintaining a "Buy" rating. (Gelonghui)

Gelonghui FinanceJan 9 16:35 · Ratings

Goldman Sachs Maintains Amgen(AMGN.US) With Buy Rating, Cuts Target Price to $370

Futu NewsJan 9 06:31 · Ratings

Goldman Sachs Adjusts Price Target on Amgen to $370 From $375, Maintains Buy Rating

MT NewswiresJan 9 00:49 · Ratings

Merck Downgraded by Truist to Hold Over Growth Concerns

Seeking AlphaJan 8 23:19

Asher Bio Announces Clinical Trial Collaboration And Supply Agreement With Amgen On Etakafusp Alfa In Combination With Bispecific T-cell Engager In Patients With Small Cell Lung Cancer

BenzingaJan 8 21:19